• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>NPG Open Access >Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial
【2h】

Combination therapy of hypertension in the elderly: a subgroup analysis of the Combination of OLMesartan and a calcium channel blocker or diuretic in Japanese elderly hypertensive patients trial

机译：老年高血压的联合治疗：日本老年高血压患者试验中OLMesartan与钙通道阻滞剂或利尿剂联合使用的亚组分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Combination of OLMesartan and a calcium channel blocker or a diuretic in Japanese elderly hypertensive patients (COLM) trial demonstrated that olmesartan combinations with a CCB or diuretic have similar effects on reducing cardiovascular risk in elderly hypertensive patients. However, the safety profiles suggest that olmesartan combined with CCB may be preferable to olmesartan combined with diuretic. In this subgroup analysis, we further evaluated the effects and safety of these combinations in elderly (65–74 years old (y.o.)) and very elderly (75–84 y.o.) hypertensive patients. In the COLM trial, 5141 patients (2918 elderly and 2223 very elderly) were randomly assigned to receive olmesartan-based therapy with either CCB or diuretic. The hazard ratios and 95% confidence intervals, respectively, in the elderly age group and in the very elderly group were: 1.04 (0.72–1.50; olmesartan plus CCB vs. olmesartan plus diuretic, P=0.85) and 0.71 (0.51–0.99, P=0.045) for the primary composite end point, and 1.07 (0.67–1.72, P=0.77) and 0.64 (0.42–0.98, P=0.036) for the composite of hard end points. The hazard ratios for stroke (fatal and non-fatal) were 1.48 (0.88–2.48; olmesartan plus CCB vs. olmesartan plus diuretic, P=0.13) and 0.63 (0.39–1.02, P=0.059) (interaction-P=0.019). Withdrawal rates from the trial, withdrawal due to serious adverse event and the incidence of any adverse event were higher in the olmesartan plus diuretic group than in the olmesartan plus CCB group in both age groups. In conclusion, angiotensin receptor blocker (ARB) and CCB combination may be preferable to an ARB and diuretic combination in the very elderly hypertensive patients for the reduction of cardiovascular risk, particularly for the reduction in stroke risk.
机译：OLMesartan与钙通道阻滞剂或利尿剂的组合在日本老年高血压患者中的研究（COLM）表明，奥美沙坦与CCB或利尿剂的组合对降低老年高血压患者的心血管风险具有相似的作用。但是，安全性研究表明，奥美沙坦联合CCB可能比奥美沙坦联合利尿剂更好。在该亚组分析中，我们进一步评估了这些组合对老年人（65-74岁（y.o.））和非常年老（75-84y.o。）高血压患者的疗效和安全性。在COLM试验中，随机分配5141例患者（2918例老年人和2223例非常老年人）接受以奥美沙坦为基础的CCB或利尿剂治疗。老年组和极老年组的危险比和95％置信区间分别为：1.04（0.72-1.50；奥美沙坦联合CCB与奥美沙坦联合利尿剂，P = 0.85）和0.71（0.51-0.99，主要复合终点为P = 0.045），硬终点复合为1.07（0.67-1.72，P = 0.77）和0.64（0.42-0.98，P = 0.036）。中风（致命和非致命）的危险比分别为1.48（0.88–2.48；奥美沙坦加CCB与奥美沙坦加利尿剂，P = 0.13）和0.63（0.39–1.02，P = 0.059）（交互作用-P = 0.019） 。在两个年龄组中，奥美沙坦加利尿剂组的试验退出率，因严重不良事件引起的退出和任何不良事件的发生率均高于奥美沙坦加CCB组。总而言之，对于降低老年高血压患者的心血管风险，尤其是降低中风风险，血管紧张素受体阻滞剂（ARB）和CCB联合治疗可能优于ARB和利尿剂联合治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号